Scarica l'app Stockscreener
132.66
0.98%
1.29
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$131.37
Aprire:
$132.015
Volume 24 ore:
4.43M
Relative Volume:
0.71
Capitalizzazione di mercato:
$230.89B
Reddito:
$43.11B
Utile/perdita netta:
$13.94B
Rapporto P/E:
16.62
EPS:
7.98
Flusso di cassa netto:
$6.78B
1 W Prestazione:
+0.05%
1M Prestazione:
+3.63%
6M Prestazione:
-2.36%
1 anno Prestazione:
+17.65%
Intervallo 1D:
$131.17
$132.84
Intervallo di 1 settimana:
$130.14
$132.96
Portata 52W:
$110.86
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Nome
Abbott Laboratories
Settore
Industria
Telefono
(224) 667-6100
Indirizzo
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Confronta ABT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
132.66 | 228.64B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
105.50 | 156.70B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
391.41 | 148.97B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.81 | 117.96B | 34.20B | 4.69B | 5.30B | 3.63 |
|
EW
Edwards Lifesciences Corp
|
81.34 | 47.69B | 5.69B | 1.41B | 577.90M | 6.95 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-18 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-06-16 | Iniziato | Leerink Partners | Market Perform |
| 2024-10-08 | Iniziato | Oppenheimer | Outperform |
| 2024-09-19 | Iniziato | Piper Sandler | Overweight |
| 2024-07-30 | Downgrade | Edward Jones | Buy → Hold |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2023-07-21 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | Reiterato | Barclays | Overweight |
| 2023-04-20 | Reiterato | Bernstein | Outperform |
| 2023-04-20 | Reiterato | JP Morgan | Overweight |
| 2023-04-20 | Reiterato | Raymond James | Outperform |
| 2023-04-20 | Reiterato | UBS | Buy |
| 2023-04-20 | Reiterato | Wolfe Research | Underperform |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2022-10-26 | Iniziato | Mizuho | Neutral |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-07-06 | Iniziato | Wolfe Research | Underperform |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-01-27 | Reiterato | Credit Suisse | Outperform |
| 2022-01-27 | Reiterato | Morgan Stanley | Overweight |
| 2022-01-27 | Reiterato | Raymond James | Outperform |
| 2022-01-27 | Reiterato | UBS | Buy |
| 2021-12-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-10-27 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | Iniziato | Redburn | Neutral |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Neutral |
| 2021-01-28 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2020-09-11 | Iniziato | Wolfe Research | Outperform |
| 2020-06-01 | Downgrade | Goldman | Neutral → Sell |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2020-02-13 | Iniziato | Goldman | Neutral |
| 2020-02-06 | Ripresa | BTIG Research | Neutral |
| 2020-01-02 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-06-13 | Reiterato | BofA/Merrill | Buy |
| 2019-02-07 | Reiterato | BofA/Merrill | Buy |
| 2019-01-02 | Downgrade | Citigroup | Neutral → Sell |
| 2018-11-30 | Aggiornamento | Goldman | Neutral → Buy |
| 2018-10-16 | Iniziato | Barclays | Overweight |
| 2018-06-27 | Iniziato | Bernstein | Outperform |
| 2018-01-30 | Reiterato | Citigroup | Neutral |
| 2018-01-25 | Reiterato | Stifel | Buy |
| 2018-01-25 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | Iniziato | Evercore ISI | Outperform |
| 2018-01-02 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-01-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-10-19 | Reiterato | Stifel | Buy |
Mostra tutto
Abbott Laboratories Borsa (ABT) Ultime notizie
Is now a turning point for Abbott LaboratoriesJuly 2025 Catalysts & Low Risk Growth Stock Ideas - Newser
Does Abbott Laboratories fit your quant trading modelMarket Sentiment Report & Daily Profit Focused Screening - Newser
What MACD and RSI say about Abbott Laboratories2025 Growth vs Value & Fast Exit and Entry Strategy Plans - Newser
Ranking Abbott Laboratories among high performing stocks via toolsPortfolio Update Report & Free Risk Controlled Daily Trade Plans - Newser
Price action breakdown for Abbott LaboratoriesWeekly Profit Analysis & Free High Accuracy Swing Entry Alerts - Newser
Price momentum metrics for Abbott Laboratories explainedJuly 2025 EndofMonth & Risk Controlled Daily Trade Plans - Newser
Stock Analysis | Abbott Laboratories OutlookNavigating Mixed Signals in a Volatile Market - AInvest
IoT in Healthcare Market to See Thriving Worldwide | Abbott Laboratories, Philips, Medtronic - openPR.com
Can a trend reversal in Abbott Laboratories lead to recoveryJuly 2025 Trends & Low Risk Profit Maximizing Plans - Newser
St. Jude Medical delivers sales growth for Abbott Labs - Star Tribune
What earnings revisions data tells us about Abbott LaboratoriesJuly 2025 Analyst Calls & Low Volatility Stock Suggestions - Newser
Abbott Laboratories: Is The Growth in Continuous Glucose Monitoring (CGM) & Ketone Monitoring Here To Stay? - Smartkarma
Abbott Laboratories stock trend outlook and recovery path2025 Year in Review & Momentum Based Trading Ideas - Newser
Applying chart zones and confluence areas to Abbott Laboratories2025 Institutional Moves & Weekly High Potential Alerts - Newser
Live market analysis of Abbott Laboratories2025 Price Action Summary & Comprehensive Market Scan Insights - Newser
How to integrate Abbott Laboratories into portfolio analysis toolsJuly 2025 PreEarnings & Fast Gaining Stock Reports - Newser
Abbott Laboratories Severance Pay: Your Rights Explained - Samfiru Tumarkin LLP
Abbott receives expanded approval for Navitor TAVR system - Cardiovascular Business
Is Abbott Laboratories stock poised for growthBuy Signal & Consistent Return Investment Signals - Newser
ABT vs. EW: Which Structural Heart Device Stock Is Worth Buying Now? - TradingView
How Abbott Laboratories (ABT) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Abbott gets EU CE Mark for expanded use of Navitor TAVI system - Seeking Alpha
Abbott Laboratories Receives CE Mark for Expanded Indication for Navitor Aortic Valve Implant - MarketScreener
Major Breakthrough: Abbott's Navitor Heart Valve Now Approved for All Surgical Risk Levels in Europe - Stock Titan
Abbott Laboratories stock chart pattern explained2025 Big Picture & Low Risk Entry Point Tips - Newser
What makes Abbott Laboratories stock price move sharplyJuly 2025 Short Interest & Capital Efficiency Focused Strategies - Newser
Formula makers have been hiding the truth — and endangering the tiniest babies | Opinion - The Tennessean
Can machine learning forecast Abbott Laboratories recoveryJuly 2025 Trends & Community Verified Trade Signals - Newser
Abbott wins expanded CE mark for Navitor TAVI system, reports updated TEER guidelines - MassDevice
Tools to assess Abbott Laboratories’s risk profileMarket Growth Summary & Real-Time Sentiment Analysis - Newser
The top Abbott stories of 2025 so far - MassDevice
What institutional flow reveals about Abbott LaboratoriesStop Loss & Momentum Based Trading Signals - Newser
Genetic Material Market Size, Trends and Top Companies (2025 – 2034 Forecast Period) - GlobeNewswire Inc.
Abbott Laboratories CEO warns tariffs are here to stay, points to new US investments [Video] - AOL.com
Abbott Laboratories Azioni (ABT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.24%
0.45%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):